AbbVie, Bristol Myers Squibb, Gilead, Merck and other drugmakers are expected on Friday afternoon ​to announce agreements ...

Boehringer Ingelheim has turned down its chance to license Nxera Pharma’s phase 2-ready schizophrenia drug candidate, depriving the Japanese drugmaker of a 60 million euro ($70 million) option payment ...

Nxera Pharma, which recently announced a number of job cuts in Cambridge, is putting on a brave face after suffering another ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing ...

Sosei Group ( ($JP:4565) ) has provided an announcement. Nxera Pharma will regain full rights to its GPR52 agonist program for schizophrenia, ...

Tokyo, Japan and Cambridge, UK, 19 December 2025 - Nxera Pharma Co. Ltd ('Nxera” or 'the Company; TSE 4565) today announces ...

FDA and European regulators have received tens of thousands of adverse event reports, including seizures and deaths, ...

A generic product for managing pain and inflammation associated with osteoarthritis (OA) in canines has been approved by FDA ...

Feline hyperthyroidism is an endocrine disorder causing an increase in thyroid hormones due to an enlarged thyroid gland in the neck of a cat. It is one of the most commonly diagnosed conditions in ...

Mepolizumab reduced COPD exacerbations in patients with eosinophilic inflammation, highlighting the potential of ...

By Ahmed Aboulenein WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay about 50% less out of pocket in ...

Numab to receive milestone payment Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration with Numab into preclinical development ...